Progesterone Prior Authorization for Menopause: What Your Rejection Means and What to Do Next

Progesterone prior authorization for menopause is rarely about you. It’s about which product got written, and which plan you happen to have.

Here’s the bottom line.“Not covered” can mean seven different things. Each one has a different fix, a different person responsible, and a wildly different timeline. Some take a phone call. Some take an appeal. Telling them apart takes about sixty seconds at the pharmacy counter — and almost nobody does it, which is why women lose weeks to the wrong process.

If your plan rejected brand Prometriumand your prescription allows substitution, FDA-approved generic progesterone is often the shortest route. On July 16, 2026, Drugs.com listed 30 × 100 mg generic capsules from $11.77, and GoodRx displayed a lowest price of $14.10 against an average retail price of $60.73.

The answer changes if: the plan rejected the generic(that’s a different rule entirely); you have a peanut allergy(Prometrium contains peanut oil — this is a safety issue before it’s an insurance one); you’re on Medicare Part D (its own clock, its own appeal ladder); or you were prescribed Bijuva (a combination capsule with product-specific criteria).

And one more thing. New York publishes its insurance appeal decisions — the full reasoning, not just the outcome. We read the menopause ones. There’s a pattern in them that will change how you talk to your doctor’s office this week.

Is this page for you?

The 7 rejection types, decoded

Everything else on this page depends on this table. “Not covered” is not a diagnosis of your problem. These seven things are.

Find your row. Read the section that matches it. You don’t need the whole page.

How does progesterone prior authorization for menopause work?

Prior authorization means a health plan requires approval before it will cover a prescription under its product-specific and plan-specific rules. A member, pharmacy, prescriber, or authorized representative may be able to start the process, but when the plan asks for clinical support, that generally has to come from the prescriber. It is a payment rule, not a review of whether your diagnosis is real.

Here’s the part that trips everyone up: plans set these rules per plan, not per company.

A single insurer might administer a commercial PPO, a Medicaid managed care plan, a Medicare Part D plan, and dozens of employer-specific plans. Each has its own drug list, its own effective date, and its own restrictions on the same medication. So when a website tells you “Cigna requires prior authorization for progesterone,” ask: which Cigna plan? On what date? For which product and strength?

We’ll be straight with you, and it’s the most useful thing on this page: no honest source can tell you your plan’s rule from your insurance company’s name. Not us, not anyone. What we can do is show you how to find it, and what each answer means.

Prior authorization isn’t the only rule — and it’s not always the one you have

Look at a real drug list. The UnitedHealthcare Community Plan of Maryland Preferred Drug List, effective July 1, 2026 — a Medicaid managed careformulary, not a commercial one — sorts drugs into Tier 1 (generic) and Tier 2 (brand), then applies seven separate restriction markers on top:

Source: UnitedHealthcare Community Plan of Maryland PDL, effective 07/01/2026. Checked July 16, 2026. This is one Medicaid plan — do not assume a commercial plan under the same brand uses the same rules.

So don’t accept the phrase “it needs a prior auth” as your answer. Ask the pharmacy to read the rejection and tell you whether the claim shows PA, diagnosis required, quantity limit, refill timing, non-formulary status, or something else. It’s on their screen. It takes seconds, and it decides everything that happens next.

How to find your actual drug list

You need four things, and they’re all findable in about ten minutes:

1. Your exact plan name.It’s on your card — and it’s usually longer and more specific than “Aetna” or “Blue Cross.”
2. Your pharmacy benefit manager (PBM).Sometimes it’s a different company from the one on the front of your card. Check the back.
3. The formulary or “preferred drug list” for your plan, at your current plan year. Log into your member portal, or search your exact plan name plus “formulary.”
4. The effective date on that document. A drug list from last plan year can be flatly wrong today.

Then find progesterone and read the markers next to it.

One wrinkle worth knowing: self-funded employer plans

If you get insurance through a large employer, there’s a decent chance your plan is self-funded— meaning your employer pays the claims and the insurance company on your card is only administering them.

Why it matters: your appeal rights, external review options, and the rules that govern them can be different from a plan the insurer actually funds. If your denial letter mentions ERISA, or your HR benefits team is the one answering coverage questions, ask directly: “Is this plan self-funded, and what external review rights do I have?”

Which product is actually on your prescription?

Generic oral progesterone, brand Prometrium, Bijuva, and compounded progesterone are four different things to an insurance plan. They can sit on different tiers, carry different restrictions, and require different paperwork. Before anyone submits anything, confirm exactly which product the pharmacy billed.

This is the single most useful question you can ask your pharmacist. Not “is it covered?” — “what exactly did you bill?”

Can the pharmacy even substitute a generic? Check this first

Before you plan around “just switch to the generic,” find out whether that’s legally available to you.

Ask the pharmacy: “Does my prescription allow generic substitution, or is it marked dispense as written?”

If your prescriber wrote DAW(“dispense as written”) or brand medically necessary, the pharmacy cannot substitute — full stop, regardless of price. You’d need your prescriber to authorize a change or issue a new prescription.

Brand Prometrium

The current U.S. label indicates Prometrium for prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets, and for secondary amenorrhea.

Note how specific that is. Plenty of women take micronized progesterone alongside a different estrogen product than conjugated estrogens tablets — that’s a clinical decision between them and their prescriber, and it’s common. But it isn’t what the label says, and that distinction sometimes shows up in coverage criteria.

The UnitedHealthcare Community Plan PDL states that it requires mandatory generic substitution on the vast majority of products when a generic equivalent is available, and that brand-name drugs may be covered in certain situations by requesting a prior authorization. That ’s not us characterizing plan behavior. That’s a plan describing itself.

Bijuva — its own criteria

Bijuva is the FDA-approved combination of estradiol and progesterone in a single capsule, for moderate to severe hot flashes and night sweats in a woman with a uterus.

Plans don’t treat one-capsule convenience as a covered reason. Here’s a real example — and it’s one plan’s policy, not a universal rule.

Mass General Brigham Health Plan’s commercial/exchange Bijuva policy, effective September 1, 2025 (rechecked July 16, 2026), is marked as a prior authorization policy. It grants authorization only when all of these are true:

1. Member is 18 years of age or older
2. Member has a diagnosis of moderate to severe vasomotor symptoms due to menopause
3. Member has had an inadequate response, intolerance, or a contraindication to an estrogen and progesterone formulation taken concurrently as separate agents

Approvals run 12 months. Read criterion 3 again. Under thispolicy, the plan wants documentation that estrogen and progesterone taken separately didn’t work for you. Your plan may word it differently. Get your plan’s actual criteria before anyone writes anything.

Compounded progesterone

Compounded drugs are prepared by a compounding pharmacy or outsourcing facility. They are not FDA-approved, and the FDA does not review them for safety, effectiveness, or manufacturing quality before they’re marketed.

What we’ll tell you is the coverage mechanics: some plans exclude compounded products from the pharmacy benefit, and others cover them only under narrow rules. So the question to ask is precise: “Is this a benefit exclusion, a non-formulary decision, or a documentation problem?” Those three answers lead to three different places, and only one of them is a paperwork fix.

→ Is Compounded HRT Safe? What Actually Differs

What changed in February 2026

On February 12, 2026, the FDA approved labeling changes for six menopausal hormone therapy products — including Prometrium. The changes removed specified boxed-warning statements about cardiovascular disease, breast cancer, and probable dementia.

What did the pharmacy actually reject?

A pharmacy rejection is a claim code, not a verdict on your treatment. Prior authorization, diagnosis required, quantity limit, refill-too-soon, non-formulary status, and benefit exclusion are different problems with different owners and different fixes. Getting the exact rejection is the step that makes every later step work.

Call the pharmacy. Ask this, word for word:

That’s it. The pharmacist can see it. It takes seconds, and it’s the difference between fixing the right problem and waiting on the wrong one.

“Diagnosis required” is not prior authorization

Most pages miss this entirely, and it’s common enough to matter.

The UnitedHealthcare Community Plan of Maryland PDL spells out the mechanism. The plan requires that the diagnosis for prescriptions in certain classes match the FDA-approved use, or a use supported by current published evidence. The diagnosis is verified at the point of sale by the pharmacy claims system. If a matching diagnosis isn’t found in the medical claim file or on the pharmacy claim, the prescription rejects right there at the counter.

But read the next line in that same document, because it matters: if the diagnosis provided still doesn’t match the approved use, a prior authorization may then be requested.

So there are two versions of this. Sometimes it’s a missing data field and the pharmacy can transmit it. Sometimes the diagnosis genuinely doesn’t meet the plan’s rule, and you’re headed for a real review. Ask which one you have before anyone starts new paperwork.

“Quantity limit”

The billed amount or day supply exceeds the plan’s rule. Common trigger: your dose changed and the claim didn’t. Check strength, capsule count, day supply, and whether something recently changed. The pharmacy can verify the billed quantity and day supply — but a plan override or prescriber action may still be needed.

“Refill too soon”

Your claim history doesn’t reflect something that changed — a new schedule, a dose change, a lost bottle, travel. Start with the pharmacy: ask them to confirm they processed the new prescription, quantity, and day supply. A corrected claim often resolves it. Sometimes you’ll still need a plan override or a prescriber note.

“Not on formulary”

The product isn’t listed as covered on your plan’s current drug list. This usually needs an exception, and your prescriber has to support it.

“Step therapy”

The plan wants you to try a preferred drug first. This is a payment rule, not a treatment instruction. Nobody at an insurance company is telling you to change your medication — and you shouldn’t change it based on a claim rejection. Ask exactly which alternative, at what dose, for how long, and what counts as having completed the step. Then take that to your prescriber.

“Excluded”

A real benefit exclusion. Ask a precise question: “Is this product excluded from my benefit, simply absent from the formulary, or excluded because it doesn’t meet the definition of a covered drug?” Those categories can carry different review rights.

Where are you in the process? (This saves people weeks)

A lot of women try to appeal before there’s anything to appeal. There are four stages, and they’re not interchangeable:

If you don’t have a written denial, you’re probably not at stage 4. Ask the plan: “What stage is my request in, and has a determination been made?”

What does generic progesterone cost, and when does paying cash make sense?

FDA-approved generic micronized progesterone is widely available at low cash prices. On July 16, 2026, Drugs.com listed 30 × 100 mg capsules from $11.77, and GoodRx displayed a lowest price of $14.10 against an average retail price of $60.73. Actual price depends on strength, quantity, pharmacy, ZIP code, stock, and savings program.

Price snapshot — checked July 16, 2026

These are savings-program and price-guide figures, not guaranteed local prices. Check your specific strength, quantity, and pharmacy before you count on any of them.

“But isn’t the generic worse?”

FDA-approved generic drugs must contain the same active ingredient, at the same strength, in the same dosage form, by the same route as the reference product, and must meet FDA’s bioequivalence requirements. They’re expected to produce the same clinical effect and safety profile under the labeled conditions of use.

One real caveat we won’t paper over:inactive ingredients can differ by manufacturer. For most people that’s irrelevant. If you have an allergy or an ingredient sensitivity, it isn’t — and that’s covered in its own section below.

And a line we won’t blur: everything above applies to FDA-approved generic micronized progesterone. It does not apply to compounded progesterone, which is not FDA-approved and is not a generic of anything.

When paying cash is the wrong move

• You’re close to your deductible or out-of-pocket maximum. A discount-card transaction generally bypasses the insurance claim, so it may not be credited toward either. Ask your plan whether it accepts a member-submitted claim before you assume.
• Your plan’s copay is actually lower. Check. Sometimes it is.
• You may need this documented later. If a future exception could depend on showing you tried something, ask the plan what evidence it accepts and whether a cash fill shows up in the records its reviewer looks at.
• Your prescription is marked dispense as written. Then this route isn’t open until your prescriber changes it.

What real appeal decisions show about documentation

New York State publishes its external appeal decisions, including the reviewers’ full clinical reasoning. Across six selected menopause-related decisions, outcomes turned on case-specific factors: the plan’s listed alternatives, chart documentation, the diagnosis and indication, therapeutic equivalence, and prior reactions. These are individual cases and do not establish approval odds or a universal rule.

When you exhaust a plan’s required internal process, some denials are eligible for external review— an independent medical reviewer, outside the insurance company. In New York’s eligible external appeal process, the reviewer’s decision binds the plan. That’s New York’s program — it doesn’t create a national standard.

But New York publishes the decisions. With the reasoning. And you can read them.

Two things before you read them. First, this is a selected set, not a survey. Second, we’re deliberately not turning six cases into a percentage. Six cases is not an approval rate, and anyone who gives you one is inventing it.

Source: New York State Department of Financial Services public external appeal database, read July 2026. NYS DFS notes that its database may not be complete, accurate, or up to date, that every case involves many individual variables, and that nothing in it promises a particular outcome in any other case. GSM = genitourinary syndrome of menopause.

What keeps showing up

Six decisions. Different drugs, different plans, different years. The same factors keep appearing.

Recurring in the decisions that went against the patient:

1. “The brand works better than the generic.” These reviewers treat FDA-approved generics as therapeutically equivalent and say so directly.
2. A failure that lives in the appeal letter but not the chart. The Vivelle-Dot decision turned on exactly this.
3. Most of the alternatives, not all.Where a plan’s criteria required failure of every formulary option in the class, three of four wasn’t enough.
4. “I’m worried about” or “I’d prefer.” Reviewers separated concern from documented failure and contraindication.
5. A mismatch between the diagnosis in the record and the treatment requested.

In the one that was overturned:named alternatives, named failures, named reactions — all documented — plus a record of sustained success on the requested product.

What your prescriber actually has to write

Medicare Part D defines what a prescriber’s supporting statement must address for a Part D tiering or formulary exception. Commercial, employer, Medicaid, and Marketplace plans may ask for similar evidence, but their criteria, forms, and appeal rights are separate and must be checked individually.

Fact 1: A Part D exception can ask them to waive the requirement itself

Most people don’t know this exists.

CMS defines a formulary exceptionunder Medicare Part D as a request to get a drug that isn’t on the plan’s formulary — or to have a utilization management requirement waived. CMS names them specifically: step therapy, prior authorization, quantity limit.

You don’t only get to satisfy the prior authorization. Under Part D, your prescriber can ask the plan to drop it.

Fact 2: On Part D, the clock starts when the supporting statement lands

For a Medicare Part D exception, the normal decision clock begins when the plan receives the prescriber’s supporting statement — not when you first called, and not when the request was opened.

There’s a backstop:under current federal rules, if the supporting statement still hasn’t arrived 14 calendar days after the exception request, the plan must make its determination within 72 hours after that 14-day period ends. So a request doesn’t float outside a clock forever. But it can absolutely sit for two weeks while everyone assumes someone else is waiting.

Medicare Part D exception standards

Source: CMS, Medicare Part D exceptions guidance. Checked July 16, 2026. These are Part D standards. If you have commercial, employer, Medicaid, or Marketplace coverage, ask your plan for its own criteria and forms.

How it can be submitted (Part D):the prescriber’s supporting statement may be given orally or in writing, though the plan may require written follow-up. It can go on CMS’s Model Coverage Determination Request Form, the plan’s own form, or — straight from CMS — any other written document, including a plain letter.

The grid that does the work

Before your prescriber sends anything, get this into the chart:

Chart documentation can be decisive. It isn’t the only thing — the indication, the plan’s criteria, the required alternatives, and therapeutic equivalence all weigh in. But it’s the one you can do something about this week.

What to say to the office

That last question is the one nobody asks. Ask it.

One line we won’t cross, and neither should you: never put a diagnosis, a code, a prior treatment, or a reaction into a request that isn’t true and supported by your record. It’s the line between advocating for yourself and misrepresenting your history to an insurer.

How long does a progesterone prior authorization take?

For Medicare Part D coverage determinations, plans generally have 72 hours for a standard request and 24 hours for an expedited request. For Part D exception requests, that period begins when the plan receives the prescriber’s supporting statement, subject to a 14-day backstop. Timelines under Medicaid, Marketplace, Medicare Advantage drug benefits, and commercial plans are program-specific and plan-specific.

Source: CMS Part D coverage determination and exception guidance; 42 CFR 423.568. Checked July 16, 2026.

That last row is not us dodging. Prescription drug timelines outside Part D genuinely vary by program, plan, PBM, and state law. Any page that gives you one number for all of them is making it up. Ask your plan what starts its clock and what its deadline is — then write it down.

If a Part D deadline passes

On Medicare Part D, when a plan doesn’t decide within the required timeframe, that’s treated as an adverse determination, and the case must be forwarded to the Independent Review Entity within 24 hours of the deadline expiring. The clock running out doesn’t mean you wait longer. It means you move up a level.

Expedited review: use it honestly

Expedited review exists for situations where waiting could seriously jeopardize your life, health, or ability to regain maximum function. Your prescriber applies that standard. Don’t ask for it just to jump the line.

What to write down on every call

What can you do while you wait?

Ask your pharmacist, prescriber, and plan what continuity options exist before you go without. Depending on the plan, options may include a claim correction, a transition or temporary supply, expedited review, or paying cash for the exact prescribed product. Do not stop, split, double, or substitute medication on your own.

Ask about a temporary supply

The UnitedHealthcare Community Plan of Maryland PDL describes a specific one: for a newly prescribed non-formulary drug, when there’s an immediate need and the prescriber can’t be reached, the claim system will accept a one-time 3-day supply.

That’s one Medicaid plan, one narrow situation. It is not a general override for every rejection, every plan, or every refill.

Other real options

• A transition fill. Some plans provide a one-time refill after you enroll, especially early in a plan year. Ask.
• Ask whether the claim just needs re-running.For “diagnosis required” or “refill too soon,” that’s sometimes the entire fix.
• Pay cash for the exact prescribed product— with all the caveats in the section above.

Before you pay cash while a request is pending

1. Can I submit a paid claim for reimbursement later?
2. Does paying cash affect my pending request?
3. Is the pharmacy filling exactly what was prescribed?
4. Is this price for the right strength and quantity?

What does a peanut allergy mean for Prometrium and generic progesterone?

Prometrium capsules contain peanut oil, and the label lists peanut allergy as a contraindication — meaning Prometrium itself should not be used by someone with that allergy. This is a safety question first and an insurance question second. FDA-approved generics may use different inactive ingredients, so the specific manufacturer being dispensed has to be checked.

Prometrium’s FDA-approved label states that the capsules contain peanut oil and are contraindicated in patients allergic to peanuts.It ’s in the contraindications section, and it’s been there since the original approval.

Then check the specific product.FDA-approved generics must match the reference product on active ingredient, strength, dosage form, and route — but inactive ingredients can differ by manufacturer. Whether the exact capsule in your bottle contains peanut oil depends on who made it. Your pharmacist can read the label for the product they’re dispensing. Don’t assume in either direction.

Where insurance re-enters:if the plan’s preferred product contains an ingredient you can’t safely take, that’s the kind of documented clinical fact a prescriber may use to request a different appropriate product. The allergy drives the medical decision. The documentation follows it — not the other way around.

Other contraindications on the label

The label also lists, among its contraindications: hypersensitivity to its ingredients; undiagnosed abnormal genital bleeding; known, suspected, or a history of breast cancer; active deep vein thrombosis or pulmonary embolism, or a history of these; active arterial thromboembolic disease such as stroke or heart attack, or a history of these; and known liver dysfunction or disease.

We list these as label facts, not advice. If any describe you, that ’s a conversation with your clinician.

How does Medicare Part D handle progesterone coverage and appeals?

A Medicare Part D formulary may cover generic progesterone, brand Prometrium, or another product, each subject to its own tier and utilization rules. Coverage cannot be inferred from Part D enrollment alone. Part D runs on its own decision timelines and a defined five-level appeal process.

If you’re on Part D, three things are different:

1. Coverage is per formulary, not per program. “I have Part D” doesn’t tell you whether your progesterone is covered.
2. The clock is defined— 72 hours standard, 24 hours expedited, and for exceptions it starts when the supporting statement lands (with that 14-day backstop).
3. The ladder is fixed.Before the appeal levels, there’s the initial coverage determination or exception request — that’s the decision, not an appeal. Then:

Source: CMS Part D appeals guidance and 2026 amount-in-controversy thresholds. Checked July 16, 2026.

Your denial notice controls everything.It names the specific reason, the filing instructions, and your deadline. File based on what your notice says — not what a website told you, including this one.

What if your prescriber won’t submit the prior authorization?

Prior authorizations impose substantial administrative work that is generally not separately reimbursed, and some practices decline to do it. In the American Medical Association’s survey of 1,000 practicing physicians conducted in late 2024, 93% said prior authorization sometimes, often, or always resulted in care delays.

Let’s be fair to your doctor for a second. This is unpaid administrative work that pulls staff away from patients, and the AMA ’s own data says physicians hate what it does to care. The system is the problem here, not usually the person.

Try these first — they’re all free

1. Ask whether the practice has a prior-authorization or medication-access coordinator. Some do. The front desk may not know to route you there.
2. Ask whether they can submit it orally.For Medicare Part D exception requests, CMS permits an oral supporting statement, though the plan may want written follow-up. Some offices will make a two-minute call when they won’t touch a fax.
3. Ask whether the pharmacy can start an electronic prior authorization that lands in the prescriber’s workflow.
4. Ask for the reference number.If they’ve already submitted, you may just need to follow up rather than escalate.

If the practice genuinely won’t do it

Then changing prescribers becomes an option worth weighing — after you’ve confirmed the current practice won’t submit the plan-required documentation, and after you’ve thought about continuity of care. That’s a real cost, not a footnote.

Midi Health — what we verified

This is The HRT Index Verification Standard applied: we read every published claim, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule.

Read that last row, because we’re not going to pretend around it. We are not telling you Midi will handle your prior authorization. Midi doesn’t publicly claim that, and we haven’t confirmed it. Anyone who tells you otherwise is selling you something.

Here’s the honest trade.Midi doesn’t take Medicare or Medicaid — if that’s your coverage, this isn’t your path. But Midi is in-network with most PPO plans in all 50 states and prescribes FDA-approved hormones by default. Those two facts happen to be exactly what determines whether a prescription can be covered at all: a clinician your plan recognizes, writing products your formulary can actually list. A cash-pay clinic writing compounded preparations gives you neither — and compounded products are the ones most likely to be excluded from your benefit outright.

The four questions to ask any provider before you pay

1. Do you bill my plan, and are you in network?
2. Does your office submit pharmacy prior authorizations, and do you handle appeals and renewals?
3. Is that work included in the visit fee?
4. Will the prescription go to my local pharmacy — and are the medications FDA-approved or compounded?

Write the answers down. A provider who answers all four clearly is telling you something. So is one who doesn’t.

Affiliate disclosure: The HRT Index may earn a commission if you use the link below, at no additional cost to you. It did not affect what we wrote — on most of this page we’re telling you to check a $12 generic and never click a provider link at all.

What we actually verified

This page is built from primary documents: FDA labels, CMS regulations, published payer policies, published state appeal decisions, and providers’ own published statements. Where we could not verify something, we say so rather than estimating.

What we read ourselves

• CMS's Medicare Part D coverage determination and formulary exception standards, and 42 CFR 423.568
• The FDA-approved Prometrium label, including the indication and contraindications
• The FDA's February 12, 2026 announcement approving labeling changes to six menopausal hormone therapy products
• Mass General Brigham Health Plan's commercial/exchange Bijuva prior authorization policy, effective 09/01/2025
• UnitedHealthcare Community Plan of Maryland's Medicaid Preferred Drug List, effective 07/01/2026 — markers, the diagnosis-required mechanism, generic substitution policy, temporary supply provision, and the oral progesterone row
• Six published New York external appeal decisions, located through the stated search and individually classified by diagnosis, product, coverage type, and outcome
• Cash pricing at two independent sources, on a dated snapshot
• Midi Health's own insurance and pricing pages

What we could NOT verify — and won’t pretend otherwise

• Your plan's rule. We didn't access any member portal or run a live claim. No public document can tell you your coverage.
• A complete picture of how plans treat progesterone. We have real rows from real documents. We do not have a measured sample across the market, which is why you won't find the words "most plans" on this page.
• Employer-specific formulary variations. These are the least public and often the most restrictive.
• Whether every manufacturer's generic progesterone contains peanut oil. Inactive ingredients vary. Ask your pharmacist about the specific product being dispensed.
• Whether Midi Health submits pharmacy prior authorizations. Not claimed by them, not confirmed by us.
• Whether any plan has changed a progesterone rule because of the February 2026 labeling action. None of the policies we reviewed said so.
• Actual approval odds. Nobody can honestly give you a number, and anyone who does is guessing.
• A complete New York appeal dataset. We read six decisions. There are more, and we're working through them.

Update log

Progesterone prior authorization FAQ

Three things to do next

1. Call the pharmacy. Ask what exactly rejected, and exactly what product they billed. Then ask whether your prescription allows a generic. Two questions, one call.
2. Match the answer to the table at the top of this page. Confirm your exact plan, its formulary effective date, and the product before you switch, pay cash, or appeal. The wrong process costs more time than the right one.
3. If a request is already in, ask the plan two things: has it received the prescriber’s supporting statement, and what date did it record as the original request date? On Part D that’s what starts the clock. On other plans, ask what does.

You didn’t do anything wrong. This is a payment rule, not a judgment about you or your treatment. It’s a system that’s frustrating by design, and the women who get through it fastest are just the ones who found out which door they were actually standing in front of.

Now you know how to find out.

Sources